IBA and Apollo Hospitals Collaborate for Enhanced Cancer Care
IBA (Ion Beam Applications S.A.), recognized as a pioneer in particle accelerator technology, has embarked on an exciting new venture with Apollo Hospitals Enterprise Limited. This partnership aims to significantly expand access to proton therapy in India by providing one Proteus®ONE system with the option for a second system. This collaboration reflects the growing commitment to advancing cancer treatment solutions in the region.
Expanding Proton Therapy in India
Over the years, IBA has built a solid working relationship with Apollo Hospitals, originating from their previous selection of the IBA Proteus®PLUS system back in 2013. This made Apollo one of the first institutions to offer proton beam therapy in India. With the new Proteus®ONE systems set for installation, Apollo Hospitals anticipates commencing patient treatments by 2028.
The Future of Treatment with Proteus®ONE
The Proteus®ONE system stands out as a leading compact proton therapy solution, designed not only for current needs but also to evolve with future technological advancements. These systems will eventually feature DynamicARC® beam delivery capabilities, ensuring patients benefit from the latest innovations in therapy. The pricing for these sophisticated systems lies between EUR 35 million to 45 million, including a multi-year maintenance contract.
Statements from Leadership
Olivier Legrain, CEO of IBA, expressed his enthusiasm for this collaboration, emphasizing how it strengthens the existing bond with Apollo Hospitals. He believes this reaffirmation of faith in IBA's technology showcases the reliability and excellence of their services, ultimately aiming to provide critical treatment for more patients in India.
Dr. Prathap C. Reddy, the visionary founder of Apollo Hospitals, echoed these sentiments by highlighting their mission to integrate cutting-edge medical technology for improved healthcare outcomes. Having already treated over 2,000 patients from numerous countries using proton therapy since 2019, Apollo is dedicated to enhancing its treatment capabilities with this new agreement.
About IBA: A Leader in Cancer Treatment Technologies
IBA (Ion Beam Applications S.A.) holds a prominent position as a worldwide leader in particle accelerator technology. It specializes in supplying advanced equipment and services in proton therapy, an essential tool in modern radiation therapy. IBA not only serves the healthcare sector but is also involved in industrial sterilization, radiopharmaceuticals, and dosimetry, employing around 2,000 professionals globally. With a commitment to social and environmental responsibility, IBA is recognized as a certified B Corporation, ensuring high standards of corporate responsibility.
About Apollo Hospitals Enterprise Limited
Since opening its first hospital in Chennai in 1983, Apollo Hospitals Enterprise Ltd has transformed the healthcare landscape in India. Today, they proudly maintain the largest integrated healthcare platform in the nation with over 10,000 beds across an extensive network of hospitals, pharmacies, and clinics. Apollo is renowned for its pioneering work in cardiac care and cancer treatment, always seeking the latest medical innovations to improve patient outcomes. With an unwavering commitment from its dedicated staff, Apollo strives to provide exemplary care, firmly positioning itself as a global leader in healthcare.
Contact Information
IBA
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@icrhealthcare.com
Frequently Asked Questions
What is the significance of the partnership between IBA and Apollo Hospitals?
The partnership enhances access to advanced proton therapy for cancer treatment in India, benefiting countless patients.
When is Apollo Hospitals expected to start using the new systems?
They expect to commence patient treatments with Proteus®ONE systems by 2028.
What is the range of investment for the Proteus®ONE system?
The investment for each system ranges from EUR 35 million to 45 million, including maintenance contracts.
How does the Proteus®ONE system benefit patients?
This system is designed to provide the latest technology, ensuring the best possible outcomes for cancer patients.
What is IBA's commitment to corporate responsibility?
IBA is a certified B Corporation, demonstrating its dedication to high social and environmental performance standards.
